From Financial Modeling Prep: 2025-03-07 07:00:05

Aytu BioPharma’s Return on Invested Capital (ROIC) is -18.15%, indicating inefficiency in using capital to generate profits. Among its peers, Co-Diagnostics, Inc. has the least negative ROIC to WACC ratio, suggesting a relatively better potential for financial improvement. AIM ImmunoTech Inc. shows a significantly negative ROIC to WACC ratio of -78.36, highlighting its struggle to generate returns.

Aytu BioPharma, Inc. (NASDAQ:AYTU) is a specialty pharmaceutical company operating in a competitive landscape with peers like Co-Diagnostics, Inc., AIM ImmunoTech Inc., iBio, Inc., Biocept, Inc., and OpGen, Inc. Aytu BioPharma’s ROIC is -18.15%, with a WACC of 23.23%, resulting in a negative ROIC to WACC ratio of -0.78, indicating inefficiency in generating profits.

Co-Diagnostics, Inc. has a ROIC of -69.90% and a WACC of 9.04%, leading to a ROIC to WACC ratio of -7.73. This is the least negative ratio among its peers, suggesting a better potential for financial improvement. AIM ImmunoTech Inc. shows a ROIC to WACC ratio of -78.36, reflecting struggles in generating returns.

OpGen, Inc. presents a ROIC of -408.66% and a WACC of 13.54%, resulting in a ROIC to WACC ratio of -30.18. These financial metrics highlight the challenges faced by companies like Aytu BioPharma, Co-Diagnostics, AIM ImmunoTech, iBio, Biocept, and OpGen in efficiently utilizing capital to generate profits.



Read more at Financial Modeling Prep:: Aytu BioPharma, Inc. (NASDAQ:AYTU) and Its Competi…